Biomime Biosorbable Polymer Sirolimus-ELuting Stent in alL-comers patIeNts Treated With Percutaneous Coronary Interventions: the BELLINI Registry
Overview
- Phase
- N/A
- Intervention
- Not specified
- Conditions
- Coronary Artery Disease
- Sponsor
- Azienda Ospedaliero Universitaria Maggiore della Carita
- Enrollment
- 250
- Locations
- 1
- Primary Endpoint
- target vessel revascularization
- Last Updated
- 11 years ago
Overview
Brief Summary
Biomime stent is a novel sirolimus-eluting stent (SES) (Meril Life Sciences Pvt. Ltd., Gujarat, India) with an ultra-thin stent platform (65 μm) and a biodegradable polymer licensed for the treatment of de novo coronary lesions. However no data regarding the efficacy and safety of this stent in an "all-comers" patient population treated with percutaneus coronary interventions (PCI) have been published so far. In this registry the investigators aimed to collect clinical and angiographic information about an extensive "all-comers" employ of this novel stent.
Investigators
Lupi Alessandro
Dr Alessandro Lupi
Azienda Ospedaliero Universitaria Maggiore della Carita
Eligibility Criteria
Inclusion Criteria
- •any coronary artery disease treated with percutaneous coronary intervention and a Biomime stent
Exclusion Criteria
- •patients \<18 years old
Outcomes
Primary Outcomes
target vessel revascularization
Time Frame: 1 year
rate of target vessel percutaneous or surgical reintervention for recurrent symptoms or inducible ischemia at follow up testes
Secondary Outcomes
- cardiac death(1 year)
- reinfarction(1 year)
- death from any cause(1 year)
- target lesion revascularization(1 year)